ADMA Biologics, Inc. (ADMA) is a biopharmaceutical company focused on developing and manufacturing plasma-derived therapies to treat immune deficiencies and infectious diseases. ADMA’s main products include intravenous immune globulin (IVIG) therapies, specifically designed to treat patients with primary immune deficiency diseases (PIDD) who need antibody support.
These therapies help boost the immune system, offering protection against infections for patients with compromised immune functions. ADMA’s portfolio also includes products targeting other infectious diseases, all aimed at improving patient outcomes through advanced plasma-derived treatments.
One of the major drivers for ADMA’s growth is the rising demand for immune globulin products as more patients with immune deficiencies or compromised immunity rely on these therapies. With the need for immune support treatments growing globally, ADMA has positioned itself as a trusted provider in the field. The company’s state-of-the-art manufacturing facilities and its commitment to quality make it a key player in this specialized segment of biopharmaceuticals. By focusing on rare and high-need medical conditions, ADMA Biologics plays an essential role in providing life-saving treatments for vulnerable patients.
For more information on ADMA Biologics and their plasma-derived therapies, visit their main website.e.
Click The Image For Current Live Chart